ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s stock price traded up 2.9% during mid-day trading on Tuesday . The stock traded as high as $6.46 and last traded at $6.42. 551,475 shares traded hands during trading, a decline of 90% from the average session volume of 5,650,446 shares. The stock had previously closed at $6.24.
Analyst Upgrades and Downgrades
Separately, Piper Sandler increased their price objective on ImmunityBio from $5.00 to $6.00 and gave the stock a "neutral" rating in a research report on Monday, April 29th.
View Our Latest Report on IBRX
ImmunityBio Stock Down 4.5 %
The company has a market cap of $4.12 billion, a PE ratio of -5.47 and a beta of 1.03. The stock has a 50-day moving average of $6.66 and a 200-day moving average of $5.22.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.04). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.03 million. Research analysts expect that ImmunityBio, Inc. will post -0.75 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale grew its stake in shares of ImmunityBio by 4.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 205,092 shares of the company's stock valued at $1,119,000 after buying an additional 8,892 shares during the last quarter. Tidal Investments LLC purchased a new stake in shares of ImmunityBio during the first quarter worth about $499,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of ImmunityBio by 3.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company's stock worth $667,000 after purchasing an additional 4,533 shares during the period. Lazard Asset Management LLC boosted its holdings in shares of ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company's stock worth $68,000 after purchasing an additional 6,593 shares during the period. Finally, Axxcess Wealth Management LLC purchased a new stake in shares of ImmunityBio during the first quarter worth about $85,000. Institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
